Cannabics Pharmaceuticals Inc. announced the expansion of its research program with new drug development projects targeting Prostate Cancer, Neurodegenerative & Mental Health diseases. The announcement of the new research projects follows promising initial preclinical results obtained in the company's in-house drug discovery facility in Rehovot, Israel. Study results indicate the potential efficacy of a variety of specific analytes for the indications tested. The experiments performed were conducted on cell lines and human biopsies obtained under Helsinki Committee approval. The company plans to continue development of these drug candidates and continue testing with animal models while entering a drug regulatory development route for each indication.